ClinicalTrials.gg
RecruitingNCT06634628iMagemHTT-009Updated Mar 13, 2026

iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009

An Early Phase 1 interventional study of Radioligand [11C]CHDI-00491009 in Huntington Disease, HD and PET Tracer, sponsored by CHDI Foundation, Inc.. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by CHDI Foundation, Inc. · Early Phase 1, Interventional, and Other

How we know · 2 judgments

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Huntington Disease by CHDI Foundation, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Huntington Disease · CHDI Foundation, Inc..

Started
2026
the only one that year
Phase 1
4 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Huntington Disease by CHDI Foundation, Inc., this one is the only one that started in 2026, is one of 4 in phase 1, and was the 11th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

2 of the 11 studies in Huntington Disease by CHDI Foundation, Inc. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Huntington Disease by CHDI Foundation, Inc., or all of them as a file.
02

Study summary

This is a FIH (first-in-human) study to evaluate the clinical utility of the radioligand [11C]CHDI-00491009 as a PET tracer that binds specifically to mutant huntingtin (mHTT) aggregates in Huntington's disease (HD).

The study is divided into three cohorts defined by the Huntington's Disease Integrated Staging System (HD-ISS): Cohort 1 - initial tracer validation (3 healthy controls (HCs)); Cohort 2 - target validation and test-retest variability (6 HD-ISS Stage 3 participants and 6 age and biological sex-matched HCs); Cohort 3 - target sensitivity (6 HD-ISS Stage 2 participants and 6 age and biological sex-matched HCs). An interim analysis (IA) will be conducted after the completion of each cohort, followed by a final analysis for the study.

In addition to imaging, exploratory biomarkers, including somatic instability index, soluble mHTT and total huntingtin (HTT), will be assessed. All participants with HD (PwHD) will have an additional blood sample drawn at the screening visit to assess the somatic instability index and will also be invited to provide an optional cerebrospinal fluid (CSF) sample for measurement of soluble mHTT and total HTT.

Read the detailed description

The PET radioligand [11C]CHDI-00491009 will be evaluated for its suitability for use in clinical research to quantify mHTT aggregates in PwHD. The PET radioligand is administered as a microdose of \<0.5 μg and will not be administered at pharmacological doses. This study has an adaptive and modular design with three consecutive cohorts. The execution of each cohort is dependent on results from the previous cohort.

Cohort 1- Screening and imaging of 3 HCs followed by an interim analysis to evaluate the tracer kinetics without target expression (mHTT) to identify potential brain penetrating radiometabolites or other issues that may interfere with accurate quantification. If the kinetics are found to be favorable during the IA and there are no other confounding issues that may interfere with accurate quantification, then the study will proceed to target validation with Cohort 2.

Cohort 2- Screening and imaging of 6 HD-ISS Stage 3 participants and 6 age and biological sex-matched HCs. 3 HCs and 3 HD participants from Cohort 2 will be imaged twice to determine variability between scans (test-retest; TRT). An IA will be conducted after completion of Cohort 2 that will establish the optimal method for quantification of signal and endpoint, as well as evaluating the tracer binding in HD compared to HC participants and determining the TRT reproducibility. Results will then be reviewed and a go/no-go decision will be made; if [11C]CHDI-00491009 demonstrates favorable kinetic and binding properties and go criteria are met, the study will proceed to Cohort 3 evaluation. Otherwise, the study will be terminated.

Cohort 3- Screening and imaging of 6 HD-ISS Stage 2 participants and 6 age and biological sex-matched HCs. An IA will be conducted after completion of Cohort 3 to evaluate binding in HD compared to HC participants.

This adaptive study design allows for review and analysis after each cohort. The progression through each level of analysis will indicate whether [11C]CHDI-00491009 is a suitable radioligand to measure mHTT aggregate levels with sufficient sensitivity to become a potential disease progression and efficacy biomarker in Huntington's disease.

03

Conditions studied

  • Huntington Disease
  • HD
  • PET Tracer
  • Positron Emission Tomography
  • Radioligand
  • Imaging
  • mHTT
  • Huntington's
  • Huntington's Disease

Browse trials for

Keywords

  • iMagemHTT
  • Huntington Disease
  • HD
  • PET Tracer
  • Positron Emission Tomography
  • radioligand
  • imaging
  • mHTT
  • huntingtin
  • Huntington's Disease
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PwHD HD-ISS Stages 2 and 3 and HC participants who:

  1. Are female or male adults, age 18-64 years old, inclusive.
  2. Have (BMI) between 19 and 35, inclusive.
  3. Have capacity to give full in writing and have read and signed the informed consent form (ICF).
  4. Are able to comply with study procedures, including fasting and blood sampling.
  5. Are able and willing to travel to the imaging center in Leuven, Belgium.
  6. Are willing to comply with the use of adequate measures.

    HD-ISS Stage 2 participants who:

  7. Have a huntingtin gene CAG expansion between 40 and 50, inclusive; and
  8. Are classified within HD-ISS Stage 2 per the HD-ISS criteria using HD-ISS Modified Stage calculator.
  9. Have a PIN score of 0.47 to 1.84 [prognostic index normed for HD (PIN) where PIN = (PIHD - 883)/1044 where PIHD = 51 x TMS + (-34) x SDMT + 7 x Age x (CAG - 34) (TMS is the UHDRS Total Motor Score, and SDMT is the UHDRS Symbol Digit Modalities Test)].

HD-ISS Stage 2 participants who:

7. Have a huntingtin gene CAG expansion between 40 and 50, inclusive; and 8. Are classified within HD-ISS Stage 2 per the HD-ISS criteria using HD-ISS Modified Stage calculator.

9. Have a PIN score of 0.47 to 1.84 [prognostic index normed for HD (PIN) where PIN = (PIHD - 883)/1044 where PIHD = 51 x TMS + (-34) x SDMT + 7 x Age x (CAG - 34) (TMS is the UHDRS Total Motor Score, and SDMT is the UHDRS Symbol Digit Modalities Test)].

HC participants who:

13. Have no known family history of HD; or 14. Have a known family history of HD and have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG \< 36).

15. Age match (+/- 5 years) and biological sex match to each HD participant in Cohort 2 and Cohort 3 (except for Cohort 1, no matching).

Exclusion criteria

Exclusion Criteria:

PwHD HD-ISS Stages 2 and 3 and HC participants who:

  1. Are currently participating in, or are less than 30 days after completing participation in, other therapeutic or imaging studies.
  2. Have previously participated in a PET imaging study in the past 12 months that, cumulatively with the current study, will exceed annual regulatory limits for radiation exposure.
  3. Have any disease, condition, or concomitant medication that significantly compromises the function of the body systems and that, in the opinion of the Investigator, might interfere with the conduct of the study or its interpretation.
  4. Are pregnant and breastfeeding females.
  5. Have concomitant use of antiplatelet or anticoagulant therapy (inclusive of acetylsalicylic acid).
  6. Have a bleeding disorder.
  7. Have a needle phobia.
  8. Have any metal objects present in the body that are incompatible with MRI.
  9. Have metal objects present in the body that are compatible with MRI and are located in the head or neck.
  10. Have any results on safety laboratory tests that, in the opinion of the Investigator, would either put the participant at risk or interfere with the conduct of the study or interpretation of data. These tests include, but are not limited to:

    • a. positive results for , HepC, -1 or HIV-2 (will also be reported as required by local/national regulations),
    • b. clinically significant, abnormal results for safety laboratory tests.

    PwHD participants who:

  11. If they are using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to participation.

    HC participants who:

  12. Have a family history of HD and have not been tested for the huntingtin gene (CAG) expansion.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Radioligand \[11C\]CHDI-00491009 3 HCs - MRI and PET Radioligand is administered 1x each person

    Radiation: Radioligand [11C]CHDI-00491009

  • Experimental
    Cohort 2

    Radioligand \[11C\]CHDI-00491009 6 HCs - MRI and PET 6 PwHD HD-ISS Stage 2 - MRI and PET Radioligand administered 2x (TRT) for 3 HCs and 3 PwHD Radioligand administered 1x for 3 HCs and 3 PwHD In addition, optional CSF collection for all PwHD

    Radiation: Radioligand [11C]CHDI-00491009

  • Experimental
    Cohort 3

    Radioligand \[11C\]CHDI-00491009 6 HCs - MRI and PET 6 PwHD HD-ISS Stage 3 - MRI and PET Radioligand administered 1x for 6 HCs and 6 PwHD In addition, optional CSF collection for all PwHD Depending on previous results and as decided by executive committee, TRT may be included in Cohort 3. A TRT decision would include one extra imaging session per participant (i.e., radioligand administered 2x per participant.)

    Radiation: Radioligand [11C]CHDI-00491009

Interventions

  • RadiationRadioligand [11C]CHDI-00491009

    Intravenous injection of radioligand in the arm with PET imaging of the brain.

06

What researchers measure

Primary outcomes

  1. The VT (volume of distribution total) of the PET radioligand will be measured with PET imaging.

    The VT (volume of distribution total) of the PET radioligand will be measured with PET imaging. \[Time Frame: Single point measure - 90 minutes scan\] VT is derived from the data collected during each PET scan.

    Time frame: Time Frame: Single point measure - 90 minutes scan

07

Study locations

1 of 1 sites recruiting
  • Universitaire Ziekenhuizen Leuven/ UZ Leuven/ UZL
    Leuven, 3000, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.

Of 19 phase 1 interventional studies under Huntington Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 10, 2024
StartActual
Feb 24, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06634628
Lead sponsor
CHDI Foundation, Inc.
Responsible party
Sponsor
First posted
Oct 10, 2024
Start date
Feb 24, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Mar 13, 2026

Study contacts

Wim Vandenberghe, MD, PhD
Contact
wim.vandenberghe@uzleuven.be
+32 16344280

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion